Financial reports
ARS
2023 FY
Annual report to shareholders
9 Apr 24
10-K
2023 FY
Annual report
4 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
14 Apr 23
10-K
2022 FY
Annual report
6 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2022 Q1
Quarterly report
16 May 22
Current reports
8-K
Passage Bio Reports Fourth Quarter and Full-year 2023 Financial Results and Provides Recent Business Highlights
4 Mar 24
8-K
Other Events
29 Feb 24
8-K
Regulation FD Disclosure
5 Jan 24
8-K
In the Court of Chancery of the State of Delaware
29 Dec 23
8-K
Passage Bio Announces Promising Initial Data from Phase 1/2 Clinical Trial of PBFT02 In FTD-GRN and Updated Strategic Priorities
20 Dec 23
8-K
Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
13 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
1 Sep 23
8-K
Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights
7 Aug 23
8-K
Departure of Directors or Certain Officers
31 Jul 23
8-K
Departure of Directors or Certain Officers
20 Jul 23
Registration and prospectus
S-8
Registration of securities for employees
4 Mar 24
S-3
Shelf registration
4 Mar 24
S-8
Registration of securities for employees
6 Mar 23
POS AM
Prospectus update (post-effective amendment)
3 Mar 22
S-8
Registration of securities for employees
3 Mar 22
POS AM
Prospectus update (post-effective amendment)
3 Mar 22
POSASR
Automatic shelf registration (post-effective amendment)
3 Mar 22
S-8
Registration of securities for employees
19 Jul 21
S-3ASR
Automatic shelf registration
5 Mar 21
S-8
Registration of securities for employees
5 Mar 21
Proxies
DEFA14A
Additional proxy soliciting materials
9 Apr 24
DEF 14A
Definitive proxy
9 Apr 24
DEFA14A
Additional proxy soliciting materials
14 Apr 23
DEF 14A
Definitive proxy
14 Apr 23
PRE 14A
Preliminary proxy
3 Apr 23
DEFA14A
Additional proxy soliciting materials
14 Apr 22
DEF 14A
Definitive proxy
14 Apr 22
DEFA14A
Additional proxy soliciting materials
14 Apr 21
DEF 14A
Definitive proxy
14 Apr 21
Other
EFFECT
Notice of effectiveness
17 Apr 24
EFFECT
Notice of effectiveness
15 Apr 22
EFFECT
Notice of effectiveness
22 Jan 21
CORRESP
Correspondence with SEC
19 Jan 21
CORRESP
Correspondence with SEC
19 Jan 21
UPLOAD
Letter from SEC
22 Dec 20
EFFECT
Notice of effectiveness
28 Feb 20
SEC STAFF
SEC staff action: Order
26 Feb 20
CERT
Certification of approval for exchange listing
25 Feb 20
CORRESP
Correspondence with SEC
25 Feb 20
Ownership
SC 13D/A
ORBIMED ADVISORS LLC
12 Apr 24
SC 13G
Lynx1 Capital Management LP
29 Mar 24
4
Kathleen Borthwick
19 Mar 24
4
Mark S Forman
19 Mar 24
4
William Chou
19 Mar 24
4
Edgar B. Cale
19 Mar 24
SC 13G/A
Lynx1 Capital Management LP
14 Feb 24
4
Kathleen Borthwick
13 Feb 24
4
Mark S Forman
13 Feb 24
4
Mark S Forman
3 Jan 24